Silo Pharma (NASDAQ:SILO) Posts Quarterly Earnings Results, Misses Expectations By $0.44 EPS

Silo Pharma (NASDAQ:SILO) announced its quarterly earnings results on Thursday. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.44), FiscalAI reports. Silo Pharma had a negative net margin of 6,726.39% and a negative return on equity of 78.94%.

Silo Pharma Price Performance

SILO stock traded down $0.02 on Friday, reaching $3.20. 27,971 shares of the company were exchanged, compared to its average volume of 54,362. The firm has a market capitalization of $4 million, a PE ratio of -0.73 and a beta of 0.71. Silo Pharma has a 12 month low of $2.75 and a 12 month high of $15.15. The stock’s fifty day moving average price is $5.29 and its 200 day moving average price is $5.55.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new position in shares of Silo Pharma during the third quarter valued at about $74,000. Geode Capital Management LLC increased its stake in Silo Pharma by 134.6% during the fourth quarter. Geode Capital Management LLC now owns 92,905 shares of the company’s stock valued at $32,000 after acquiring an additional 53,309 shares during the period. AdvisorShares Investments LLC raised its holdings in Silo Pharma by 64.3% in the 4th quarter. AdvisorShares Investments LLC now owns 599,507 shares of the company’s stock valued at $204,000 after acquiring an additional 234,629 shares in the last quarter. Finally, DRW Securities LLC bought a new stake in shares of Silo Pharma in the 4th quarter worth approximately $113,000. Institutional investors own 5.58% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Silo Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Silo Pharma

Silo Pharma, Inc (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health.

The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents.